West Cancer Center & Research Institute is the leader in comprehensive adult cancer care led by providers to provide the most positive outcomes though research, novel therapies, advanced treatments, and cancer prevention to all patients, regardless of socioeconomic status. With over 40 years of oncology expertise, 100+ specialists, 8 locations and over 47,000 patients in 2021- West is positioned as the first choice for cancer care in the Mid-South and a national model for comprehensive care.
Dr. Somer on Hesitancy Regarding Biosimilar Use in Oncology
November 15th 2019Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, explains where the hesitancy regarding biosimilar use in oncology.
Dr. Schwartzberg on the Use of Therapeutic Biosimilars in Breast Cancer
November 7th 2019Lee S. Schwartzberg, MD, FACP, chief medical officer, OneOncology, chief and professor of medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, and executive director, West Cancer Center, discusses the use of therapeutic biosimilars in breast cancer.
Dr. Gieschen on Toxicities Associated With Radiation Therapy in Prostate Cancer
April 17th 2019Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the toxicities associated with radiation therapy in prostate cancer.
Dr. Somer on Optimal Combinations in mRCC
March 27th 2019Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses optimal combinations for the treatment of patients with metastatic renal cell carcinoma (mRCC) in the frontline setting.
Dr. Rayford on Improving Stratification of Patients With Prostate Cancer
February 9th 2019Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses ways to improve stratification of patients with prostate cancer.
Dr. Rayford on Racial Risk Stratification in Prostate Cancer
January 16th 2019Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses a study aiming to refine racial risk stratification in prostate cancer.
Assessing Risk Stratification Across Pivotal Prostate Cancer Trials
January 8th 2019Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.
Dr. Somer on Treatment Selection Considerations in RCC
January 8th 2019Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).
Dr. Gieschen on Patient Selection for Radiation in Prostate Cancer
December 14th 2018Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses patient selection for radiation in the treatment of prostate cancer.